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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Midazolam (MDZ),a water-soluble benzodiazepine,
can be administered via several routes,including
intravenously (IV),intramuscularly (IM) and buccal
routes to terminate convulsions.It may be a suitable
alternative to diazepam to stop convulsions in
children with severe malaria,especially at peripheral
healthcare facilities.The pharmacokinetics of MDZ
have not been described in African children,in
whom factors such as the aetiology and nutritional
status may inﬂuence the pharmacokinetics.
WHAT THIS STUDY ADDS
• Administration of MDZ (IV,IM,or buccal) at the
currently recommended dose (0.3 mg kg
-1) resulted
in rapid achievement of median maximum plasma
concentrations of MDZ within the range
64–616 ng ml
-1,with few clinically signiﬁcant
cardio-respiratory effects.A single dose of MDZ
rapidly terminated (within 10 min) seizures in all
(100%),9/12 (75%) and 5/8 (63%) children following
IV,IM and buccal administration,respectively.
Although IM and buccal MDZ may be the preferred
treatment for children in the pre-hospital settings
the efﬁcacy appears to be poorer.
AIM
To investigate the pharmacokinetics and clinical efﬁcacy of intravenous (IV),
intramuscular (IM) and buccal midazolam (MDZ) in children with severe
falciparum malaria and convulsions.
METHODS
Thirty-three children with severe malaria and convulsions lasting 5m i n
were given a single dose of MDZ (0.3 mg kg-1)I V( n = 13),IM (n = 12) or via the
buccal route (n = 8).Blood samples were collected over 6 h post-dose for
determination of plasma MDZ and 1′-hydroxymidazolam concentrations.
Plasma concentration–time data were ﬁtted using pharmacokinetic models.
RESULTS
Median (range) MDZ Cmax of 481 (258–616),253 (96–696) and 186 (64–394)
ng ml-1 were attained within a median (range) tmax of 10 (5–15),15 (5–60) and
10 (5–40) min,following IV,IM and buccal administration,respectively.Mean
(95% conﬁdence interval) of the pharmacokinetic parameters were:AUC(0,•)
596 (327,865),608 (353,864) and 518 (294,741) ng ml-1 h;Vd 0.85 l kg-1;
clearance 14.4 ml min-1 kg
-1,elimination half-life 1.22 (0.65,1.8) h,respectively.
A single dose of MDZ terminated convulsions in all (100%),9/12 (75%) and
5/8 (63%) children following IV,IM and buccal administration.Four children
(one in the IV,one in the IM and two in the buccal groups) had respiratory
depression.
CONCLUSIONS
Administration of MDZ at the currently recommended dose resulted in rapid
achievement of therapeutic MDZ concentrations.Although IM and buccal
administration of MDZ may be more practical in peripheral healthcare
facilities,the efﬁcacy appears to be poorer at the dose used,and a different
dosage regimen might improve the efﬁcacy.
Re-use of this article is permitted in accordance with the Creative Commons Deed,Attribution 2.5,which does not permit commercial exploitation.
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Acute convulsions are common in children admitted to
hospitals in resource-poor countries, with over a ﬁfth of
childrenhavingahistoryofconvulsionsintheirpresenting
illness in some areas [1]. In malaria-endemic areas, falci-
parum malaria is the most common cause of convulsions
[2]. Multiple and prolonged convulsions are often refrac-
tory to treatment,and are associated with increased mor-
tality [3, 4] and neurocognitive deﬁcits in some survivors
[5, 6]. Early treatment of convulsions may improve
outcome in this group.The ideal anticonvulsant should be
easy to administer,provide a rapid and sustained duration
of anticonvulsant action,and be safe [7].Benzodiazepines
are often used as the drugs of choice for rapid termination
of convulsions [8].
Diazepam is commonly used as the standard ﬁrst-line
treatment for acute convulsions in resource-poor coun-
tries, because it is inexpensive, rapidly acting, and widely
available.However,it has several disadvantages.Diazepam
is routinely administered IV,but this is not a practical route
in many peripheral healthcare facilities in many parts of
Africa.Intravenous administration of diazepam has a rapid
onset of action, but it is rapidly redistributed into fatty
tissues,leading to recurrence of convulsions [9].Moreover,
administration of multiple doses of diazepam is undesir-
able,especially in children with severe malaria,since respi-
ratory depression may interfere with the hyperpnoea that
compensates for the acidosis [10,11].In many parts of the
world, the parenteral preparation of diazepam is adminis-
teredrectally,butiserraticallyabsorbedfromthisroute[9].
Furthermore, it is unacceptable in some cultures. The IM
route is commonly used in many peripheral healthcare
units in Africa, but diazepam is slowly and erratically
absorbed [12].
Midazolam (MDZ) has several pharmacokinetic and
pharmacological properties that support its use.It can be
administered via several routes, including IV [13–15], IM
[16–19] and via the buccal cavity [20–24]. It is effective in
childhood status epilepticus refractory to other anticon-
vulsants (diazepam, lorazepam, phenytoin and phenobar-
bital) [25, 26]. It has a rapid onset of action and shorter
eliminationhalf-life;itisthereforelesslikelythandiazepam
to accumulate and cause respiratory depression on
repeated administration [14].However,there are a number
of issues that may limit the use of MDZ in severe malaria.
Firstly,it is associated with decreased peripheral perfusion,
which may limit absorption of IM administered drugs.Sec-
ondly, midazolam may impair the compensatory hyperp-
noea and aggravate hypotension [27]. Lastly, the
pharmacokinetics of MDZ may be inﬂuenced by hepatic
dysfunction [28], antimalarials e.g. quinine which inhibits
the metabolism of MDZ in vitro [29] and the plasma from
patients with severe malaria [30].
ThepharmacokineticsofMDZhavenotbeendescribed
in African children, particularly those with severe malaria.
Moreover, the therapeutic concentration of MDZ has not
been deﬁned [31]. The objectives of this study were to
describe the pharmacokinetics and clinical efﬁcacy and
safety of MDZ following IV,IM or buccal administration for
treatment of Kenyan children with severe malaria and
acute convulsions.
Methods
Study site and study design
This was an open-label, non-randomized, uncontrolled
study. Children were recruited per route of drug adminis-
tration (IV,IM and buccal,respectively) until the minimum
number (target n = 12) had completed the full blood sam-
pling procedure for the pharmacokinetic study.The study
was conducted after approval by the Kenya Medical
Research Institute (KEMRI)/National Ethical Review Com-
mittee and the Research Ethics Committee (Liverpool
School of Tropical Medicine, Liverpool, UK).The study was
conductedattheKiliﬁDistrictHospital,locatedinamalaria
endemic area on the Kenyan coast. A KEMRI research
centre is situated within the hospital. Severely ill children
who present to the hospital are assessed in the outpatient
department by government-employed clinical ofﬁcers.
Children with severe malaria are admitted to the six-bed
paediatric high dependency unit.
Study participants
All children admitted to the high dependency unit were
eligible for the study if they: (i) were aged between 6
months and 13 years; (ii) had features of severe malaria
(blood-ﬁlm positive Plasmodium falciparum plus one or
more of the following:prostration (inability to sit or breast
feed), coma, prolonged or recurrent convulsions, respira-
tory distress (deep breathing or intercostal recession), cir-
culatory collapse, severe anaemia (haemoglobin <5 0gl
-1
plus respiratory distress) or jaundice) [32, 33]; (iii) had a
convulsion lasting 5 min, or 3 convulsions lasting
<5 min within 1 h; and (iv) if the child’s parent(s)/
guardian(s) gave written informed consent.Children were
excluded if: (i) informed consent could not be obtained
(they were treated with IV diazepam or IM paraldehyde);
(ii) they had received diazepam before admission/
recruitment into the study; (iii) they had compromised
cardio-respiratory function (which might be worsened by
administration of a benzodiazepine); and (iv) they had
detectable MDZ concentrations in the pre-dose blood
sample (excluded at the data analysis stage). Children
exited the study if informed consent was withdrawn.
Clinical care
Intravenous access was obtained by ﬁxing F.E.P. polymer
cannulae into the forearm veins,one for IV administration
of ﬂuids and drugs, and the other (in the opposite arm)
for blood sampling. A venous blood sample (6 ml) was
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including: quantitative malaria parasite count, blood
culture, measurement of blood glucose, venous blood
gases,electrolytes(sodiumandpotassium),lactate,andfull
blood count. Plasma from a portion of the blood (0.5 ml)
was stored (-80°C) until analyzed for baseline MDZ and
1′-hydroxymidazolam concentrations.
Hypotension (deﬁned as a systolic blood pressure
<70 mm Hginchildrenaged<1year,or<80 mm Hginchil-
dren aged >1 year) was treated by administering boluses
of normal saline (20 ml kg
-1 over 15 min) until the blood
pressure was normal. Standard care was provided as pre-
viously described [9]. All convulsions were recorded on a
proforma (type, duration, lowest oxygen saturation and
blood glucose during the convulsion), with a 5-min post-
ictal evaluation of the level of consciousness, respiratory
rate and oxygen saturation. The nursing staff performed
clinical assessments every 4–6 h, documenting vital signs,
recurrence of convulsions and level of consciousness.Phy-
sicians reassessed the children at 4 and 24 h after admis-
sion and on a daily basis thereafter.
Malaria was treated with parenteral quinine (Ipca
Laboratories Ltd, Kandivli Estate, Mumbai, India) (loading
dose,15 mg kg
-1;maintenance dose:10 mg kg
-1 12 hourly)
diluted in 10 ml kg
-1 of 5% dextrose) infused over 2 h [34]
until patients could tolerate oral medication, when anti-
malarial therapy was completed with a full course of
sulfadoxine–pyrimethamine alone or in combination with
amodiaquine (according to Kenyan national guidelines at
the time of the study).Antimalarial treatment was stopped
if three consecutive blood smears at 8-hourly intervals
were all negative.
Broad-spectrum antibiotics (chloramphenicol sodium
succinate: loading dose of 40 mg base kg
-1 plus mainte-
nance dose of 25 mg base kg
-1 6 hourly;and benzyl peni-
cillin: 60 mg base kg
-1 6 hourly) [35, 36] were given to all
children as presumptive treatment for bacteraemia. This
antibiotic regimen was continued until CSF and blood
culture results were available.
Children with convulsions lasting 5 min were treated
with a single dose (0.3 mg kg
-1) of MDZ (Dormicum®;
15 mg per 3 ml; F. Hoffmann–La Roche Ltd, Basel,
Switzerland),administered IV as a slow bolus over 1–2 min
(to reduce the chances of respiratory depression),or as an
IM injection into the anterior aspect of the thigh,or via the
buccal cavity. For buccal administration, the appropriate
volume (range: 0.3–1.0 ml) of the IV preparation of MDZ
(15 mg per 3 ml) was drawn into a 1 ml syringe.The child’s
lipswerepartedandtheMDZsolutionsquirtedaroundthe
buccal mucosa between the gum and cheeks [23]. If the
child had copious amounts of secretions following drug
administration (often due to the ongoing convulsions),
the nursing personnel had the discretion to commence
suction to clear the airway (to avoid the risk of aspiration).
If the child was still having a convulsion 5–10 min after
administration of MDZ, then IM paraldehyde (0.4 ml kg
-1;
100%v/v,MaynePharmaPlc,Warwickshire,UK)wasadmin-
istered.If the convulsions continued following administra-
tion of the ﬁrst-line drugs (MDZ or paraldehyde), then
phenytoin (Faulding Pharmaceuticals Plc.,UK) was admin-
isteredataloadingdose(18 mg kg
-1)asanIVinfusionover
20 min, followed by a maintenance dose (2.5 mg kg
-1 12
hourly) [37]. At 30 min, if the convulsions still persisted,
phenobarbital (100 mg ml
-1; Lab RENAUDIN, France) was
administered IV as a loading dose (15 mg kg
-1) infused
over 20 min,followed by maintenance doses (2.5 mg kg
-1)
at 24 and 48 h [38].
Children with recurrent (3) convulsions lasting
<5 min or status epilepticus (continuous clinical seizure
activity lasting 30 min) were also treated with a loading
doseofIVphenobarbital.Childrenwhofailedtorespondto
phenobarbital and were still convulsing at 60 min from
start of treatment (refractory status epilepticus) were
given sodium thiopental (500 mg, Biocheme, GmbH,
Vienna, Austria) as an IV bolus (4 mg kg
-1) infused over
1 min, followed by a maintenance dose of 4 mg kg
-1 h
-1
infused over 2 h under close supervision of a clinician.
Blood sampling
Serialvenousbloodsamples(0.5 ml)forthedetermination
of plasma MDZ and 1′-hydroxymidazolam concentrations
were collected before MDZ administration (pre-dose) and
at5,10,15,20,30,40,60 min,and2,3,4,5and6 hafterdrug
administration. The blood was collected into lithium-
heparinized tubes and immediately centrifuged (1500 g;
5 min) at room temperature. Plasma was separated and
transferred into polyvinyl tubes and stored at -80°C until
analyzed for MDZ and 1′-hydroxymidazolam.
Clinical measurements
The times of administration of MDZ and termination of
convulsions were recorded. Vital signs (respiratory rate,
pulse rate,arterial blood pressure),oxygen saturation and
level of consciousness (Blantyre coma score) [28] were
recorded at every blood sampling time point. The total
number, duration, and pattern of convulsions within the
6-h sampling period were also recorded. Efﬁcacy was
assessed by termination of the convulsion, latency (time
from MDZ injection to convulsion control), and time to
next convulsion.In a few cases,patients received a second
or third anticonvulsant (paraldehyde,phenytoin or pheno-
barbital) after the single dose of MDZ.Therefore,the dura-
tion of convulsion free period was reported descriptively
as‘no recurrence’.
The primary outcome measure, therapeutic success,
was the cessation of visible signs of seizure activity within
10 min of administration of MDZ without respiratory
depression and without another convulsion within 6 h.
Respiratory depression was deﬁned as a fall in oxygen
saturationtolessthan95%ordecreaseinrespiratoryeffort
sufﬁcient to require assisted breathing via bag-and-mask
after administration of MDZ.Children who had respiratory
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ﬂumazenil,abenzodiazepinereceptorbindingsiteantago-
nist [39].
Determination of midazolam and
1-hydroxymidazolam by LC–MS–ESI
Plasma concentrations of MDZ and 1′-hydroxymidazolam
were simultaneously determined using a sensitive and
selective reversed-phase high-performance liquid chro-
matography method coupled with electrospray ionization
mass spectrometry (LC–ESI–MS) [40]. Brieﬂy, MDZ,
1′-hydroxymidazolam and 1′-chlordiazepoxide (internal
standard) were extracted from alkalinized (pH 9.5)
plasma samples using liquid–liquid extraction with
1-chlorobutane. Separation was performed on a
reversed-phase HyPURITY™ Elite C18 analytical column
(100 mm ¥ 2.1 mm i.d.; 5 mm) by isocratic elution using an
acidic (pH 2.8) mobile phase (water-acetonitrile; 75 : 25%
(v/v) containing formic acid (0.1%, v/v)). Flow rate was
0.2 ml min
-1. The mass spectrometer was operated in the
positive ion mode at the protonated molecular ions [M+l]
+
of parent drug and metabolite. Calibration curves
were linear (r  0.995) over the plasma concentration
range of 15–600 ng ml
-1 (MDZ) and 5–200 ng ml
-1 (1′-
hydroxymidazolam). The limits of detection and quantiﬁ-
cation were 2 ng ml
-1 a n d5n gm l
-1, respectively, for both
MDZ and 1′-hydroxymidazolam. The intra-assay coefﬁ-
cients of variation (CVs) at 40,250 and 500 ng ml
-1 of MDZ
were 4.4%,6.5% and 1.3% (n = 7 in all cases),respectively;
the CV values for 1’-hydroxymidazolam at 30, 80 and
180 ng ml
-1 were 2.4%, 9.7% and 4.9% (n = 7 in all cases),
respectively. The inter-assay CVs at the above concentra-
tionswere6.9%,4.1%(n = 7inbothcases)and6.5%(n = 8),
respectively,for MDZ and 12.8%,7.5% (n = 7 in both cases)
and 5.0% (n = 8), respectively, for 1’-hydroxymidazolam.
There was no interference from other commonly
co-administered (anticonvulsant, antimicrobial, anti-
pyretic, and antimalarial) drugs in these children.
4′-Hydroxymidazolam did not interfere with the assay,but
it was not detected in all the patient samples.
Pharmacokinetic analysis
Plasma MDZ and 1’-hydroxymidazolam concentration–
time data after IV,IM and buccal administration were used
to estimate standard pharmacokinetic parameters (clear-
ance,elimination half-life,apparent volume of distribution
and area under the plasma drug concentration–time
curve) using the pharmacokinetic programTopFit (Version
2.0) [41] and standard pharmacokinetic methods [42].The
maximum plasma drug concentration (Cmax) and the corre-
sponding time to achieve this value (tmax) were noted
directly.
Statistical analysis
The estimated pharmacokinetic parameters were summa-
rized as mean or median (95% conﬁdence interval (95%
CI)) or median (range). The 95% CI for the differences
between the means or medians were calculated using a
commercially available statistical program Conﬁdence
Interval Analysis (CIA) [43].The Mann–Whitney U-test was
used to compare demographic and pharmacokinetic
parameters between the IV, IM and buccal treatment
groups, using Stata™ (version 9.0) (Stata Corporation,
Texas,USA).A P value of <0.05 was considered statistically
signiﬁcant.
Results
Demographic characteristics
Thirty-three children (median age,26 months;range:7–86
months)wererecruitedintothestudy(Table 1).Therewere
no statistically signiﬁcant differences in the demographic
and laboratory parameters on admission among the study
groups, and they were similar to most children admitted
with severe malaria in this population [9].
Control of convulsions
A single dose of MDZ terminated convulsions in all (13/13;
100%),9/12 (75%) and 5/8 (63%) children,following IV,IM,
and buccal administration,respectively.These convulsions
were terminated within a median time of 10 min (Table 2),
otherwise other antiepileptic drugs were used. Two chil-
dren had convulsions that were refractory to all the anti-
convulsants used.The therapeutic success rate (deﬁned as
cessation of visible signs of seizure activity within 10 min
of administration of MDZ without respiratory depression
and without another convulsion within 6 h) was 46%,50%
and 40%, respectively, for the IV, IM and buccal routes,
respectively.
Cardio-respiratory effects
Four children (one in the IV, one in the IM and two in the
buccal groups) (12%) had respiratory depression immedi-
ately after MDZ administration. Flumazenil successfully
reversed the respiratory depressant effects of MDZ.
Deaths
Four children (one in the IM group and three in the buccal
group) died. However, none of these children died during
the 6-h sampling period. All these children had cerebral
malaria and multiple convulsions, three had hypoglycae-
mia on admission,and in addition,one child had bacterial
meningitis. The deaths were attributed to complications
associated with severe falciparum malaria such as severe
metabolic acidosis and hypoglycaemia.
Pharmacokinetics
Thepharmacokineticproﬁlesof1′-hydroxymidazolampar-
alleled those of the parent compound (Figure 1).The ratios
of AUC(0,•)o f1 ′-hydroxymidazolam to parent drug were
0.49–0.55 for the three routes of administration (Table 3).
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of quantiﬁcation in all the children who received mida-
zolam by IV,IM or buccal routes.
Midazolam was rapidly absorbed after IM and buccal
administration. Median plasma MDZ Cmax values within
the range 64–616 ng ml
-1 were achieved within 15 (range
5–60) min in all the children,for the three routes of admin-
istration (Figure 1 and Table 3). Compared with the IV
route,Cmax values were statistically lower following IM and
buccal administration,but the values were not statistically
signiﬁcantly different between IM and buccal administra-
tion (Table 3).The Cmax values (range 96–360 ng ml
-1 for IM
and 185–394 ng ml
-1 for the buccal route) for those chil-
dren whose convulsions were not terminated were within
the 95% CI for the group (Figure 2).
Six (18%) children (three in the IV, one in the IM and
two in buccal groups, respectively) were malnourished
(weight-for-age Z (WAZ) score -3.0; range -3.1 to -4.2)
(Table 1).The Cmax (96 ng ml
-1) and tmax (1.0 h) for the mal-
nourished child in the IM group were outside the 95% CI
for this group, but the MDZ Cmax values for IV (range 258–
268 ng ml
-1) and buccal (range 163–187 ng ml
-1) routes,
and the corresponding tmax values (range 0.08–0.167 h),
respectively,were within the 95% CI for the two groups.
Table 1
Demographic characteristics and biochemical parameters of children administered a single dose (0.3 mg kg-1) of midazolam (MDZ) intravenously (i.v.),
intramuscularly (i.m.) or via buccal cavity
Parameter IV midazolam IM midazolam Buccal midazolam P value
Demography
Number of children 13 12 8 –
Gender (M : F) 5:8 5:7 4:4 –
Age (months)* 27 (7–39) 25 (9–96) 26 (7–64) 0.852
Weight (kg) 10.4 (8.7, 12.1) 11.3 (8.8, 13.9) 10.1 (7.9, 12.4) 0.872
Weight-for-age Z (WAZ) score -1.6 (-3.6, 1.8) -1.3 (-4.2, 0.0) -1.6 (-4.0, -0.1)
Number of malnourished children (WAZ 3) 3 (23%) 1 (8%) 2 (25%) –
Laboratory parameters
Haemoglobin (g dl-1) 7.3 (6.1, 8.5) 7.9 (6.2, 9.7) 7.6 (4.5, 10.7) 0.611
WBC (¥106); ml-1* 11.8 (8.2, 15.5) 15.6 (8.7, 22.4) 19.7 (6.2, 33.2) 0.321
Parasite count (ml-1); geometric mean 36 163 69 255 26 242 –
Sodium (mmol l-1) 138 (136, 140) 134 (130, 137) 133 (131, 135) 0.059
Potassium (mmol l-1) 4.4 (4.0, 4.7) 4.2 (3.8, 4.6) 3.9 (3.3, 4.6) 0.295
Creatinine (mmol l-1) 55 (31, 79) 53 (40, 66) 41 (32, 50) 0.198
Blood glucose (mmol l-1) 8.1 (4.4, 11.7) 6.7 (4.2, 9.2) 4.3 (-0.65, 8.3) 0.294
Hypoglycaemia (blood glucose <2.2 mmol l-1); (n) 11 4–
pH 7.16 (6.98, 7.33) 7.25 (7.18, 7.32) 7.12 (6.96, 7.28) 0.854
Base excess -10.5 (-14.9, -5.9) -8.3 (-11.5, -5.2) -12.3 (-15.2, -9.4) 0.852
Values are expressed as mean (95% conﬁdence interval; CI) or *median (range), except parasite count, which is expressed as geometric mean.
Table 2
Clinical progress and outcome
IV midazolam IM midazolam Buccal midazolam
Number of children 13 12 8
Blantyre coma score on admission 3 (0–5) 2 (0–5) 3 (0–5)
Blood transfusion (n) 1 (8%) 2 (17%) 0 (0%)
Number of convulsions after admission 3 (1–uncountable) 2 (1–uncountable) 1 (1–3)
Patients with convulsions controlled with a single dose of midazolam 13 (100%) 9 (75%) 5 (63%)
Latency (time from initial midazolam administration to convulsion control) (min) 2 (1–6) 5 (1–5) 3.5 (1–5)
Patients with recurrence convulsions after midazolam* 6 (46%) 2 (22%) 0 (0%)
Patients requiring additional anticonvulsants:
Paraldehyde 3 (23%) 1 (8%) 0 (0%)
Phenobarbital 4 (31%) 4 (33%) 3 (38%)
Phenytoin 3 (23%) 3 (25%) 3 (38%)
Thiopental 1 (8%) 0 (0%) 0 (0%)
Patients with respiratory depression after midazolam 1 (8%) 1 (8%) 2 (25%)*
Deaths 0 (0%) 1 (8%) 3 (38%)
Values are expressed as number (percentage) or number (range). *Statistically signiﬁcantly different from the IV MDZ group (P = 0.029).
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This study shows that MDZ administered IV is more effec-
tive in the termination of convulsions than via the IM and
buccal routes in children within a hospital setting,but it is
associated with a risk of respiratory depression.Because of
its good aqueous solubility, MDZ offers superior uptake
and rapid absorption after IM [19] and buccal [44] admin-
istration. After an initial rapid fall in MDZ concentra-
tion characterized by the redistribution phase, the IV
concentration–time plot showed a log-linear decline
(elimination phase).The parallel decline in plasma concen-
trations of MDZ and 1′-hydroxymidazolam and the ratio of
AUC1-hydroxymidazolam :A U C midazolam <1 (Table 3) are consistent
with formation rate-limited metabolite kinetics, as
reported in young healthy volunteers [45].
Pharmacokinetics
The pharmacokinetics of MDZ in this study are similar to
other studies in children and neonates [13, 17, 46]. The
results from the present study show that the exposure
Table 3
Pharmacokinetic parameters of midazolam (MDZ) and 1′-hydroxymidazolam following administration of a single dose (0.3 mg kg-1) of MDZ intravenously
(IV),intramuscularly (IM) or via the buccal cavity in children with severe malaria and convulsions
Parameter IV midazolam IM midazolam Buccal midazolam
95% CI for the difference between means or ‡medians
IV vs. IM IV vs. buccal IM vs. buccal
Number of children 12 11 8
Midazolam
Cmax (ng ml-1)‡ 481 (358, 554) 253 (145, 475) 186 (64, 394) 79, 322* 135, 369* -37, 220
tmax (h)‡ 0.167 (0.08, 0.167) 0.25 (0.167, 0.67) 0.27 (0.12, 0.50) 0.0, 0.33 -0.25, 0.0 -0.16, 0.25
t1/2 (elimination) (h) 1.22 (0.65, 1.8) – –
AUC (0,•) (ng ml-1 h) 596 (327, 865) 608 (353, 864) 518 (294, 741) -366, 340 -433, 278 -413, 233
CL (ml-1 min-1 kg-1) 14.4 (9.2, 19.7) – –
Vd (l kg-1) 0.85 (0.49, 1.13) – –
Bioavailability (F) Assume 100% 102% 87%
1-Hydoxymidazolam**
Cmax (ng ml-1)‡ 64 (44, 103) 82 (18, 116) 46 (16, 102) -29, 42 -56, 20 -24, 66
tmax (h)‡ 0.59 (0.167, 1.0) 0.67 (0.5, 2.0) 1.0 (0.5, 2.0) -0.67, 0.33 -0.33, 0.83 -0.33, 0.50
AUC(0,•) (ng ml-1 h) 197 (118, 276) 270 (151, 389) 189 (61, 317) -56, 203 -139, 123 -87, 249
AUC1–hydroxymidazolam : AUCmidazolam 0.55 (0.11, 0.99) 0.49 (0.27, 0.72) 0.55 (0.07, 1.04) -0.44, 0.55 -0.63, 0.64 0.37, 0.49*
Values are presented as mean (95% conﬁdence interval, CI) or ‡median (95% CI). *Statistically signiﬁcantly different from the IV MDZ group. **n = 6 for buccal MDZ; calculation
of pharmacokinetic parameters were possible in only these number of cases.
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Mean (SD) plasma concentration vs. time proﬁles of midazolam
(MDZ) and 1′-hydroxymidazolam following administration of a
single dose (0.3 mg kg
-1) of midazolam intravenously (n = 12; MDZ; ;
1′-hydroxymidazolam: ), intramuscularly (n = 11; MDZ: ,
1′-hydroxymidazolam: ) or via the buccal cavity (n = 8; MDZ:
,1 ′-hydroxymidazolam: ) to children with severe malaria and
convulsions
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Figure 2
Relationship between midazolam (MDZ) plasma maximum concentra-
tions (Cmax)a n dtmax and efﬁcacy in termination of convulsions in children
following administration of a single dose (0.3 mg kg-1) of MDZ intrave-
nously (IV) (: seizures terminated, n = 12); intramuscularly (IM) ( :s e i -
zuresterminated,n = 8; :seizuresnotterminated,n = 3);orviathebuccal
route (:seizures terminated,n = 5;:seizures not terminated,n = 3)
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almost complete bioavailability (Table 3). In comparison,
the absolute bioavailability for IM MDZ was approximately
87% in children aged 5.9 years [17] and 87  18% in adult
epileptic patients [16].The high bioavailability after IM and
buccal administration of MDZ supports its administration
by this route.
4′-Hydroxymidazolam concentrations were below the
limitofquantiﬁcationinallthechildrenwhoreceivedMDZ
by IV, IM or buccal routes. In 10 critically ill adult patients
with acute renal failure on continuous venovenous
haemoﬁltration, the amounts of 4′-hydroxymidazolam
and 4′-hydroxymidazolam-glucuronide excreted were less
than 1% of the amounts of 1′-hydroxymidazolam and
1′-hydroxymidazolam-glucuronide [47]. Therefore, it is
likely that in the children in our study, the 4′-
hydroxymidazolam metabolite was formed in very low
quantities,andsubsequentlyrapidlyconjugatedandelimi-
nated in urine. 1’-Hydroxymidazolam is as potent as the
parent drug [48];it may contribute to the pharmacological
activity of the drug following oral administration.
Two children had copious amounts of saliva following
administration of buccal MDZ, necessitating suction of
the airway. MDZ Cmax values of 161 and 63 ng ml
-1 were
achieved within 5 and 30 min, respectively; these values
were within the 95% CI for the group. However, convul-
sions were terminated in both cases.None of the children
had any aspiration.
The pharmacokinetic parameters of MDZ are reported
to exhibit a considerable degree of inter-individual vari-
ability, particularly in critically ill patients [49]. There was
approximately a two-fold variation in plasma MDZ clear-
ance in patients in this study.Hughes et al. [50] reported a
higher plasma MDZ clearance (13 ml
-1min
-1 kg
-1)i n
children aged 3 years compared with infants and
children up to 2 years of age (3.1 ml
-1min
-1 kg
-1 and
2.3 ml
-1min
-1 kg
-1,respectively).
Efﬁcacy
In the present study, the primary outcome measures
included cessation of visible signs of convulsive activity
within 10 min of drug administration, without respiratory
depression requiring medical intervention, and without
another convulsion within the 6-h study period.Following
administration of buccal MDZ, convulsions were termi-
nated within 10 min in ﬁve out of eight children (63%),
which is in accord with values (75–78%) reported in previ-
ous studies [20,21,23].Buccal MDZ is rapidly effective [44]
and in previous studies,buccal administration terminated
convulsions within 3–20 min of administration in 56–84%
of cases [20,22–24].Buccal MDZ was shown to be at least
as effective as rectal diazepam in the acute treatment of
seizures[21,24].InarecentstudyofUgandanchildren[20],
buccal MDZ was superior to rectal diazepam for treatment
ofchildrenwithprolongedconvulsions,butthebeneﬁtsof
buccal MDZ were markedly evident in children with con-
vulsions that were not associated with falciparum malaria.
Most of the children in the present study had recur-
renceofconvulsionsfollowinginitialterminationwithIVor
IM MDZ (Table 2). The incidence of recurrence of convul-
sions after administration of MDZ has been previously
reported:11–31%forIM[19,51],14–30%forbuccal[20,22,
24] administration, and 57% for continuous MDZ IV infu-
sionforthecontrolofrefractorystatusepilepticus[52];this
is attributed to the short elimination half-life (about 1–3 h)
of MDZ. The relatively lower efﬁcacy of buccal and IM
administration compared with IV MDZ may be attributed
to a lag in the absorption phase, especially following IM
administration. The prolonged absorption phase may be
caused by malaria which is associated with decreased
peripheral perfusion. One malnourished child had lower
Cmax and longer tmax values compared with non-
malnourished children. It is likely that MDZ was poorly
absorbed from the IM injection site.
Regimen
ThedosesofMDZusedinchildreninpreviousstudieswere
variable,and there are few pharmacokinetic data to justify
thedosageregimens.ThedoseofMDZusedinthepresent
study (0.3 mg kg
-1) is within the range (0.2–0.3 mg kg
-1)
usedinpreviousstudiesinchildren[22–24],butlowerthan
the buccal dose (0.5 mg kg
-1) used in recent studies by
Mpimbaza et al.[20] and McIntyre et al. [24].In the present
study, only a single dose of MDZ was given. Repeated
administrationofMDZmayresultinmoreeffectivecontrol
of seizures.Accumulation of drug and its metabolites may
not occur (because of the short elimination half-lives).The
weight-adjusted dose of buccal MDZ that would be sufﬁ-
cient to control seizures in this group has not been
deﬁned,anditisstillunclearwhetherefﬁcacyandsafetyof
this dose would be dependent on age.
Potential drug interactions
The effect of other drugs on the pharmacokinetics of
MDZ may be clinically signiﬁcant. All the children in
this study received quinine, which is metabolized to
3-hydroxyquinine by CYP3A4 [53] and has been shown to
interactwithMDZinvitro[54].However,itwasnotpossible
to measure plasma concentrations of quinine in this study
because only limited blood volumes could be taken from
these severely ill young children.MDZ has an intermediate
to high extraction ratio of approximately 0.4 [55], and its
clearance may vary with both hepatic blood ﬂow and
hepatic enzyme activity.The variability in the latter may be
muchmoreimportant,becauseMDZiseliminatedthrough
oxidation by hepatic enzymes,with a restricted capacity.
Adverse events
Four (12%) children in this study experienced respiratory
depression,compared with 1.2% and 5% in recent studies
[20, 24]. Respiratory depression associated with convul-
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which is benzodiazepine therapy [56]. Four deaths (12%)
occurred among the children who were enrolled in the
present study. However, none of the children died during
the6-hstudyperiod;allthechildrendiedatleast24 hafter
MDZ administration. Thus, it is unlikely that MDZ was
responsible for the deaths.
Limitations of the study
The limitations of this study include:(i) a non-randomized
studydesignwhichpotentiallymayhaveintroducedselec-
tion bias in the allocation of patients into the different
routesofMDZadministration;and(ii)thesmallnumbersin
each group limits the comparison between the groups.
Further studies are required to compare the efﬁcacy and
frequency of adverse events between the different routes
of administration.
In conclusion, the pharmacokinetic data presented in
this study show a high bioavailability and reliable plasma
concentrations following IM and buccal MDZ.Administra-
tion of MDZ (IV, IM or buccal) at the currently recom-
mended dose resulted in rapid attainment of maximum
plasma concentrations of MDZ above 60 ng ml
-1 but it was
associatedwithahighincidenceofrespiratorydepression.
Although IV MDZ terminated seizures in all children with
severe malaria, there was a high rate of recurrence of sei-
zures. Intramuscular and buccal administration of MDZ
may be more practical in most rural healthcare facilities in
sub-Saharan Africa, but the efﬁcacy appears to be poorer
at the dose used, and a different dosage regimen might
improve the efﬁcacy of IM and buccal MDZ. We recom-
mend that MDZ (0.3 mg kg
-1) should be administered IV,
but in peripheral health centres with no facilities for IV
cannulation, then IM and buccal MDZ may be used cau-
tiously as an alternative. Ideally, MDZ should be adminis-
tered together with a long acting anticonvulsant in
children with severe malaria and convulsions.
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